In the case of prostate cancer, most genetic alterations in PTEN and TP53 are deletions or mutations (Figure 2B), which result in a reduction of their expression in concordance with the acceleration of carcinogenesis [29, 30]. This evidence concerns the gene PTEN and prostate carcinoma.